Loading…
Cardiotonic agents. 7. Prodrug derivatives of 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one
The cardiotonic agent 4-ethyl-1,3-dihydro-5-4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H- imidazol-2-one (1) was found to have low bioavailability when administered orally to rats and dogs. A series of N-acyl derivatives, an underutilized prodrug of acidic NH compounds, has been synthesized and tested f...
Saved in:
Published in: | Journal of medicinal chemistry 1992-04, Vol.35 (7), p.1267-1272 |
---|---|
Main Authors: | , , , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-a354t-889f81e0c91d90af8d424938a7c33d005ff293d6bc9725a9a8955ebcbe98c71b3 |
---|---|
cites | |
container_end_page | 1272 |
container_issue | 7 |
container_start_page | 1267 |
container_title | Journal of medicinal chemistry |
container_volume | 35 |
creator | Shaw, Kenneth J Erhardt, Paul W Hagedom, Alfred A Pease, Cynthia A Ingebretsen, William R Wiggins, Jay R |
description | The cardiotonic agent 4-ethyl-1,3-dihydro-5-4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H- imidazol-2-one (1) was found to have low bioavailability when administered orally to rats and dogs. A series of N-acyl derivatives, an underutilized prodrug of acidic NH compounds, has been synthesized and tested for their ability to improve the oral bioavailability of 1. Reaction of the monosodium salt of 1 with various anhydrides afforded the N-1 monoacylimidazolones with surprisingly high regioselectivity. In addition to the prodrugs, acylation of 1 with propionic or phenylacetic anhydride led to the novel 3H-pyrrolo[1,2-c]imidazole-3,5(2H)-diones 6. The prodrugs showed a significant increase in the partition coefficients with a minor decrease in the aqueous solubility. The benzoyl derivative 4b exhibited the highest stability in both pH 1.5 and 7.4 buffer solutions. Further evaluation of 4b showed rapid conversion to 1 in canine plasma (t1/2 = 38 min), and human plasma (t1/2 = 10 min). Oral studies indicated that the bioavailability of 4b was increased to greater than 75% (compared to less than 20% for 1), and hemodynamic studies demonstrated that the selective inotropic profile of 1 was retained. |
doi_str_mv | 10.1021/jm00085a014 |
format | article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_72891077</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>72891077</sourcerecordid><originalsourceid>FETCH-LOGICAL-a354t-889f81e0c91d90af8d424938a7c33d005ff293d6bc9725a9a8955ebcbe98c71b3</originalsourceid><addsrcrecordid>eNptkM9rFDEUgIModa2ePAtzsoq-NT83yVEWbYWCFasIIiGTZNqsM5OazBSn-Mc7Mov24Ok9-D7egw-hxwSvCabk1a7DGCthMeF30IoIioErzO-iFcaUAt1Qdh89KGU3a4xQdoAOiNhgzvQK_dra7GMaUh9dZS9CP5R1JdfVWU4-jxeVDzle2yFeh1KlpuIQhsupBfKSgY-Xk88JBHzl8IxCt0cnELvo7U2ad5ja53Xob9LUfgN6i1BIfXiI7jW2LeHRfh6iT2_fnG9P4PT98bvt61OwTPABlNKNIgE7TbzGtlGeU66ZstIx5jEWTUM185vaaUmF1VZpIULt6qCVk6Rmh-jpcvcqpx9jKIPpYnGhbW0f0liMpEoTLOUsvlhEl1MpOTTmKsfO5skQbP60Nrdaz_aT_dmx7oL_5y5xZw4Lj2UIP_9im7-bjWRSmPOzj-bD5y_imCpi2OwfLb51xezSmPs5yn8__wbuKJLf</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>72891077</pqid></control><display><type>article</type><title>Cardiotonic agents. 7. Prodrug derivatives of 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one</title><source>American Chemical Society</source><creator>Shaw, Kenneth J ; Erhardt, Paul W ; Hagedom, Alfred A ; Pease, Cynthia A ; Ingebretsen, William R ; Wiggins, Jay R</creator><creatorcontrib>Shaw, Kenneth J ; Erhardt, Paul W ; Hagedom, Alfred A ; Pease, Cynthia A ; Ingebretsen, William R ; Wiggins, Jay R</creatorcontrib><description>The cardiotonic agent 4-ethyl-1,3-dihydro-5-4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H- imidazol-2-one (1) was found to have low bioavailability when administered orally to rats and dogs. A series of N-acyl derivatives, an underutilized prodrug of acidic NH compounds, has been synthesized and tested for their ability to improve the oral bioavailability of 1. Reaction of the monosodium salt of 1 with various anhydrides afforded the N-1 monoacylimidazolones with surprisingly high regioselectivity. In addition to the prodrugs, acylation of 1 with propionic or phenylacetic anhydride led to the novel 3H-pyrrolo[1,2-c]imidazole-3,5(2H)-diones 6. The prodrugs showed a significant increase in the partition coefficients with a minor decrease in the aqueous solubility. The benzoyl derivative 4b exhibited the highest stability in both pH 1.5 and 7.4 buffer solutions. Further evaluation of 4b showed rapid conversion to 1 in canine plasma (t1/2 = 38 min), and human plasma (t1/2 = 10 min). Oral studies indicated that the bioavailability of 4b was increased to greater than 75% (compared to less than 20% for 1), and hemodynamic studies demonstrated that the selective inotropic profile of 1 was retained.</description><identifier>ISSN: 0022-2623</identifier><identifier>EISSN: 1520-4804</identifier><identifier>DOI: 10.1021/jm00085a014</identifier><identifier>PMID: 1560439</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Animals ; Biological Availability ; Cardiotonic Agents - chemical synthesis ; Cardiotonic Agents - pharmacokinetics ; Chromatography, High Pressure Liquid ; Dogs ; Drug Stability ; Half-Life ; Humans ; Hydrogen-Ion Concentration ; Imidazoles - chemistry ; Imidazoles - pharmacokinetics ; Imidazoles - pharmacology ; Molecular Structure ; Prodrugs - chemical synthesis ; Prodrugs - pharmacokinetics ; Structure-Activity Relationship</subject><ispartof>Journal of medicinal chemistry, 1992-04, Vol.35 (7), p.1267-1272</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a354t-889f81e0c91d90af8d424938a7c33d005ff293d6bc9725a9a8955ebcbe98c71b3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/jm00085a014$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/jm00085a014$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>314,780,784,27064,27924,27925,56766,56816</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1560439$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shaw, Kenneth J</creatorcontrib><creatorcontrib>Erhardt, Paul W</creatorcontrib><creatorcontrib>Hagedom, Alfred A</creatorcontrib><creatorcontrib>Pease, Cynthia A</creatorcontrib><creatorcontrib>Ingebretsen, William R</creatorcontrib><creatorcontrib>Wiggins, Jay R</creatorcontrib><title>Cardiotonic agents. 7. Prodrug derivatives of 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one</title><title>Journal of medicinal chemistry</title><addtitle>J. Med. Chem</addtitle><description>The cardiotonic agent 4-ethyl-1,3-dihydro-5-4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H- imidazol-2-one (1) was found to have low bioavailability when administered orally to rats and dogs. A series of N-acyl derivatives, an underutilized prodrug of acidic NH compounds, has been synthesized and tested for their ability to improve the oral bioavailability of 1. Reaction of the monosodium salt of 1 with various anhydrides afforded the N-1 monoacylimidazolones with surprisingly high regioselectivity. In addition to the prodrugs, acylation of 1 with propionic or phenylacetic anhydride led to the novel 3H-pyrrolo[1,2-c]imidazole-3,5(2H)-diones 6. The prodrugs showed a significant increase in the partition coefficients with a minor decrease in the aqueous solubility. The benzoyl derivative 4b exhibited the highest stability in both pH 1.5 and 7.4 buffer solutions. Further evaluation of 4b showed rapid conversion to 1 in canine plasma (t1/2 = 38 min), and human plasma (t1/2 = 10 min). Oral studies indicated that the bioavailability of 4b was increased to greater than 75% (compared to less than 20% for 1), and hemodynamic studies demonstrated that the selective inotropic profile of 1 was retained.</description><subject>Animals</subject><subject>Biological Availability</subject><subject>Cardiotonic Agents - chemical synthesis</subject><subject>Cardiotonic Agents - pharmacokinetics</subject><subject>Chromatography, High Pressure Liquid</subject><subject>Dogs</subject><subject>Drug Stability</subject><subject>Half-Life</subject><subject>Humans</subject><subject>Hydrogen-Ion Concentration</subject><subject>Imidazoles - chemistry</subject><subject>Imidazoles - pharmacokinetics</subject><subject>Imidazoles - pharmacology</subject><subject>Molecular Structure</subject><subject>Prodrugs - chemical synthesis</subject><subject>Prodrugs - pharmacokinetics</subject><subject>Structure-Activity Relationship</subject><issn>0022-2623</issn><issn>1520-4804</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><recordid>eNptkM9rFDEUgIModa2ePAtzsoq-NT83yVEWbYWCFasIIiGTZNqsM5OazBSn-Mc7Mov24Ok9-D7egw-hxwSvCabk1a7DGCthMeF30IoIioErzO-iFcaUAt1Qdh89KGU3a4xQdoAOiNhgzvQK_dra7GMaUh9dZS9CP5R1JdfVWU4-jxeVDzle2yFeh1KlpuIQhsupBfKSgY-Xk88JBHzl8IxCt0cnELvo7U2ad5ja53Xob9LUfgN6i1BIfXiI7jW2LeHRfh6iT2_fnG9P4PT98bvt61OwTPABlNKNIgE7TbzGtlGeU66ZstIx5jEWTUM185vaaUmF1VZpIULt6qCVk6Rmh-jpcvcqpx9jKIPpYnGhbW0f0liMpEoTLOUsvlhEl1MpOTTmKsfO5skQbP60Nrdaz_aT_dmx7oL_5y5xZw4Lj2UIP_9im7-bjWRSmPOzj-bD5y_imCpi2OwfLb51xezSmPs5yn8__wbuKJLf</recordid><startdate>19920401</startdate><enddate>19920401</enddate><creator>Shaw, Kenneth J</creator><creator>Erhardt, Paul W</creator><creator>Hagedom, Alfred A</creator><creator>Pease, Cynthia A</creator><creator>Ingebretsen, William R</creator><creator>Wiggins, Jay R</creator><general>American Chemical Society</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19920401</creationdate><title>Cardiotonic agents. 7. Prodrug derivatives of 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one</title><author>Shaw, Kenneth J ; Erhardt, Paul W ; Hagedom, Alfred A ; Pease, Cynthia A ; Ingebretsen, William R ; Wiggins, Jay R</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a354t-889f81e0c91d90af8d424938a7c33d005ff293d6bc9725a9a8955ebcbe98c71b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>Animals</topic><topic>Biological Availability</topic><topic>Cardiotonic Agents - chemical synthesis</topic><topic>Cardiotonic Agents - pharmacokinetics</topic><topic>Chromatography, High Pressure Liquid</topic><topic>Dogs</topic><topic>Drug Stability</topic><topic>Half-Life</topic><topic>Humans</topic><topic>Hydrogen-Ion Concentration</topic><topic>Imidazoles - chemistry</topic><topic>Imidazoles - pharmacokinetics</topic><topic>Imidazoles - pharmacology</topic><topic>Molecular Structure</topic><topic>Prodrugs - chemical synthesis</topic><topic>Prodrugs - pharmacokinetics</topic><topic>Structure-Activity Relationship</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shaw, Kenneth J</creatorcontrib><creatorcontrib>Erhardt, Paul W</creatorcontrib><creatorcontrib>Hagedom, Alfred A</creatorcontrib><creatorcontrib>Pease, Cynthia A</creatorcontrib><creatorcontrib>Ingebretsen, William R</creatorcontrib><creatorcontrib>Wiggins, Jay R</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of medicinal chemistry</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shaw, Kenneth J</au><au>Erhardt, Paul W</au><au>Hagedom, Alfred A</au><au>Pease, Cynthia A</au><au>Ingebretsen, William R</au><au>Wiggins, Jay R</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Cardiotonic agents. 7. Prodrug derivatives of 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one</atitle><jtitle>Journal of medicinal chemistry</jtitle><addtitle>J. Med. Chem</addtitle><date>1992-04-01</date><risdate>1992</risdate><volume>35</volume><issue>7</issue><spage>1267</spage><epage>1272</epage><pages>1267-1272</pages><issn>0022-2623</issn><eissn>1520-4804</eissn><abstract>The cardiotonic agent 4-ethyl-1,3-dihydro-5-4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H- imidazol-2-one (1) was found to have low bioavailability when administered orally to rats and dogs. A series of N-acyl derivatives, an underutilized prodrug of acidic NH compounds, has been synthesized and tested for their ability to improve the oral bioavailability of 1. Reaction of the monosodium salt of 1 with various anhydrides afforded the N-1 monoacylimidazolones with surprisingly high regioselectivity. In addition to the prodrugs, acylation of 1 with propionic or phenylacetic anhydride led to the novel 3H-pyrrolo[1,2-c]imidazole-3,5(2H)-diones 6. The prodrugs showed a significant increase in the partition coefficients with a minor decrease in the aqueous solubility. The benzoyl derivative 4b exhibited the highest stability in both pH 1.5 and 7.4 buffer solutions. Further evaluation of 4b showed rapid conversion to 1 in canine plasma (t1/2 = 38 min), and human plasma (t1/2 = 10 min). Oral studies indicated that the bioavailability of 4b was increased to greater than 75% (compared to less than 20% for 1), and hemodynamic studies demonstrated that the selective inotropic profile of 1 was retained.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>1560439</pmid><doi>10.1021/jm00085a014</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0022-2623 |
ispartof | Journal of medicinal chemistry, 1992-04, Vol.35 (7), p.1267-1272 |
issn | 0022-2623 1520-4804 |
language | eng |
recordid | cdi_proquest_miscellaneous_72891077 |
source | American Chemical Society |
subjects | Animals Biological Availability Cardiotonic Agents - chemical synthesis Cardiotonic Agents - pharmacokinetics Chromatography, High Pressure Liquid Dogs Drug Stability Half-Life Humans Hydrogen-Ion Concentration Imidazoles - chemistry Imidazoles - pharmacokinetics Imidazoles - pharmacology Molecular Structure Prodrugs - chemical synthesis Prodrugs - pharmacokinetics Structure-Activity Relationship |
title | Cardiotonic agents. 7. Prodrug derivatives of 4-ethyl-1,3-dihydro-5-[4-(2-methyl-1H-imidazol-1-yl)benzoyl]-2H-imidazol-2-one |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T10%3A26%3A48IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Cardiotonic%20agents.%207.%20Prodrug%20derivatives%20of%204-ethyl-1,3-dihydro-5-%5B4-(2-methyl-1H-imidazol-1-yl)benzoyl%5D-2H-imidazol-2-one&rft.jtitle=Journal%20of%20medicinal%20chemistry&rft.au=Shaw,%20Kenneth%20J&rft.date=1992-04-01&rft.volume=35&rft.issue=7&rft.spage=1267&rft.epage=1272&rft.pages=1267-1272&rft.issn=0022-2623&rft.eissn=1520-4804&rft_id=info:doi/10.1021/jm00085a014&rft_dat=%3Cproquest_cross%3E72891077%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-a354t-889f81e0c91d90af8d424938a7c33d005ff293d6bc9725a9a8955ebcbe98c71b3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=72891077&rft_id=info:pmid/1560439&rfr_iscdi=true |